Clinical Trial

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-lable, single arm, non-randomized study to evaluate the primary safety and efficacy of the novel bispecific AbTCR (anti-CD19/CD22)-T cells in patients with relapsed or refractory B-cell lymphoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-05.
Trial Details
NCT Number NCT07168291
Lead Sponsor First Affiliated Hospital Xi'an Jiaotong University
Collaborators: Eureka Therapeutics Inc.
Conditions Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Burkitt Lymphoma
Enrollment 3 participants
Start Date 2025-12-31
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-17